Megan Miller

5.3k total citations · 1 hit paper
57 papers, 3.5k citations indexed

About

Megan Miller is a scholar working on Immunology, Dermatology and Surgery. According to data from OpenAlex, Megan Miller has authored 57 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 13 papers in Dermatology and 12 papers in Surgery. Recurrent topics in Megan Miller's work include Psoriasis: Treatment and Pathogenesis (17 papers), Dermatology and Skin Diseases (11 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Megan Miller is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (17 papers), Dermatology and Skin Diseases (11 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Megan Miller collaborates with scholars based in United States, Canada and Germany. Megan Miller's co-authors include Mark Pohlman, Anne S. Pohlman, Rhonda Barr, Amy Bowman, Linda Spears, Cheryl L. Esbrook, Jesse B. Hall, John P. Kress, Amy J. Pawlik and Gregory A. Schmidt and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Immunology.

In The Last Decade

Megan Miller

54 papers receiving 3.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial

2009 2.1k citations William D. Schweickert, Mark Pohlman et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Megan Miller United States	21	2.1k	867	724	580	438	57	3.5k
Mark O. Farber United States	28	786 0.4×	1.1k 1.2×	181 0.3×	376 0.6×	433 1.0×	68	3.0k
Heidi L. Frankel United States	30	1.3k 0.6×	526 0.6×	65 0.1×	1.8k 3.2×	131 0.3×	113	3.9k
Leah Passmore United States	16	835 0.4×	427 0.5×	324 0.4×	396 0.7×	81 0.2×	21	2.1k
Matti Tarkka Finland	31	190 0.1×	542 0.6×	57 0.1×	1.3k 2.2×	90 0.2×	166	3.6k
Pamela Berry United States	15	226 0.1×	2.4k 2.7×	66 0.1×	91 0.2×	147 0.3×	27	3.2k
George Kasotakis United States	30	555 0.3×	341 0.4×	92 0.1×	1.2k 2.0×	52 0.1×	89	2.5k
Abdulla A. Damluji United States	23	801 0.4×	294 0.3×	184 0.3×	653 1.1×	428 1.0×	143	3.1k
Mark C. Bellamy United Kingdom	32	360 0.2×	430 0.5×	19 0.0×	1.3k 2.2×	411 0.9×	87	2.9k
Shahzad Shaefi United States	28	1.0k 0.5×	697 0.8×	30 0.0×	818 1.4×	623 1.4×	84	3.0k
Thomas Corbridge United States	23	284 0.1×	989 1.1×	93 0.1×	221 0.4×	143 0.3×	65	1.8k

Countries citing papers authored by Megan Miller

Since Specialization

Citations

This map shows the geographic impact of Megan Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Miller more than expected).

Fields of papers citing papers by Megan Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Miller. The network helps show where Megan Miller may publish in the future.

Co-authorship network of co-authors of Megan Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Miller. A scholar is included among the top collaborators of Megan Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Miller. Megan Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krawczyk, Noa, Megan Miller, Julián Santaella-Tenorio, et al.. (2025). Self‐reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities. Addiction.

Miller, Megan, Katherine Wheeler-Martin, Amanda M. Bunting, Magdalena Cerdá, & Noa Krawczyk. (2025). Changes in Synthetic Opioid–Involved Youth Overdose Deaths in the United States: 2018–2022. PEDIATRICS. 155(6). 1 indexed citations

Krawczyk, Noa, Jenny Scott, Megan Miller, et al.. (2025). Envisioning a Humane and Accessible US Methadone Treatment System: Generating Policy and Practice Recommendations From the Liberate Methadone Movement. PubMed. 47(2). 316–325.

Krawczyk, Noa, Megan Miller, Honora Englander, et al.. (2024). Toward a Consensus on Strategies to Support Opioid Use Disorder Care Transitions Following Hospitalization: A Modified Delphi Process. Journal of General Internal Medicine. 40(5). 1048–1058. 3 indexed citations

Blauvelt, Andrew, Kenneth B. Gordon, Richard G. Langley, et al.. (2024). Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2. Journal of Investigative Dermatology. 144(12). 2816–2819.e2.

Schuh, Michael J., et al.. (2023). High-Evidence, Actionable Phenotype Gene Distribution in a Multispecialty, Tertiary Care Clinic: Potentially Actionable Genes and a Referring Department Profile. INNOVATIONS in pharmacy. 14(2). 3–3. 1 indexed citations

Blauvelt, Andrew, Diamant Thaçi, Kim Papp, et al.. (2023). Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. British Journal of Dermatology. 189(1). 132–134. 8 indexed citations

Bissonnette, Robert, Andreas Pinter, Laura K. Ferris, et al.. (2023). 78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1. Journal of Investigative Dermatology. 143(11). S345–S345. 3 indexed citations

Strober, Bruce, Laura C. Coates, Mark Lebwohl, et al.. (2023). Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug Safety. 47(1). 39–57. 31 indexed citations

10.

Lebwohl, Mark, Joseph F. Merola, Megan Miller, et al.. (2023). Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure. British Journal of Dermatology. 189(1). 42–52. 21 indexed citations

11.

Mease, Philip J., M. Shawi, Ya‐Wen Yang, et al.. (2022). AB0892 Targeted Safety Analyses of Guselkumab: Long-Term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis. Annals of the Rheumatic Diseases. 81. 1572–1573. 1 indexed citations

12.

Reich, Kristian, Kenneth B. Gordon, Bruce Strober, et al.. (2022). Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology. 36(12). 2393–2400. 20 indexed citations

13.

Griffiths, C.E.M., Kim Papp, Michael Song, et al.. (2020). Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. Journal of Dermatological Treatment. 33(2). 848–856. 32 indexed citations

14.

Reich, Kristian, April W. Armstrong, Peter Foley, et al.. (2020). Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. American Journal of Clinical Dermatology. 21(6). 881–890. 27 indexed citations

15.

Byham‐Gray, Laura, et al.. (2016). Predictors of preoperative weight loss achievement in adult bariatric surgery candidates while following a low-calorie diet for 4 weeks. Surgery for Obesity and Related Diseases. 13(6). 1041–1051. 12 indexed citations

16.

Pohlman, Mark, William D. Schweickert, Anne S. Pohlman, et al.. (2010). Feasibility of physical and occupational therapy beginning from initiation of mechanical ventilation*. Critical Care Medicine. 38(11). 2089–2094. 212 indexed citations

17.

Schweickert, William D., Mark Pohlman, Anne S. Pohlman, et al.. (2009). Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. The Lancet. 373(9678). 1874–1882. 2129 indexed citations breakdown →

18.

Brand, Rhonda M., et al.. (2009). Alcohol consumption induces regional immune dysfunction (39.22). The Journal of Immunology. 182(Supplement_1). 39.22–39.22. 1 indexed citations

19.

Dougall, William C., Xiaolan Qian, Norman Peterson, et al.. (1994). The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.. PubMed. 9(8). 2109–23. 158 indexed citations

20.

Miller, Megan, et al.. (1984). Adult respiratory distress syndrome associated with miliary tuberculosis. A case report.. PubMed. 65(1). 27–8. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact